{"id":"https://openalex.org/W4416740915","doi":"https://doi.org/10.1158/1535-7163.30733800","title":"Supplementary Methods from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma","display_name":"Supplementary Methods from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma","publication_year":2025,"publication_date":"2025-11-27","ids":{"openalex":"https://openalex.org/W4416740915","doi":"https://doi.org/10.1158/1535-7163.30733800"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.30733800","doi":"https://doi.org/10.1158/1535-7163.30733800","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30733800","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.30733800","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035186994","display_name":"Kohei Takano","orcid":"https://orcid.org/0000-0002-3759-9972","observed_orcids":["https://orcid.org/0000-0002-3759-9972"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kohei Takano","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3759-9972","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027077299","display_name":"Yoichi Munehira","orcid":"https://orcid.org/0000-0002-9309-8128","observed_orcids":["https://orcid.org/0000-0002-9309-8128"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yoichi Munehira","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9309-8128","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064636391","display_name":"Mana Hatanaka","orcid":"https://orcid.org/0000-0003-4527-7145","observed_orcids":["https://orcid.org/0000-0003-4527-7145"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mana Hatanaka","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4527-7145","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067758620","display_name":"Ryo Murakami","orcid":"https://orcid.org/0000-0003-2795-1554","observed_orcids":["https://orcid.org/0000-0003-2795-1554"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryo Murakami","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2795-1554","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052693166","display_name":"Yoshihiro Shibata","orcid":"https://orcid.org/0000-0001-9009-4343","observed_orcids":["https://orcid.org/0000-0001-9009-4343"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yoshihiro Shibata","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9009-4343","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081097359","display_name":"Takeshi Shida","orcid":"https://orcid.org/0000-0002-7482-1990","observed_orcids":["https://orcid.org/0000-0002-7482-1990"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takeshi Shida","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7482-1990","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013888056","display_name":"Kosuke Takeuchi","orcid":"https://orcid.org/0000-0003-3284-6484","observed_orcids":["https://orcid.org/0000-0003-3284-6484"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kosuke Takeuchi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3284-6484","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028704793","display_name":"Sho Takechi","orcid":"https://orcid.org/0000-0003-0880-5578","observed_orcids":["https://orcid.org/0000-0003-0880-5578"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sho Takechi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0880-5578","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081580649","display_name":"Toshiki Tabata","orcid":"https://orcid.org/0000-0003-4346-8474","observed_orcids":["https://orcid.org/0000-0003-4346-8474"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Toshiki Tabata","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4346-8474","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103087279","display_name":"Takashi Shimada","orcid":"https://orcid.org/0000-0002-4310-4235","observed_orcids":["https://orcid.org/0000-0002-4310-4235"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takashi Shimada","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4310-4235","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047431823","display_name":"Shuhei Kishikawa","orcid":"https://orcid.org/0000-0002-9729-7423","observed_orcids":["https://orcid.org/0000-0002-9729-7423"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shuhei Kishikawa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9729-7423","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070095749","display_name":"Yumi Matsui","orcid":"https://orcid.org/0000-0003-3901-0225","observed_orcids":["https://orcid.org/0000-0003-3901-0225"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yumi Matsui","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3901-0225","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040655229","display_name":"Osamu Ubukata","orcid":"https://orcid.org/0000-0002-8133-9705","observed_orcids":["https://orcid.org/0000-0002-8133-9705"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Osamu Ubukata","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8133-9705","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076762350","display_name":"Takahiko Seki","orcid":"https://orcid.org/0000-0002-1531-3291","observed_orcids":["https://orcid.org/0000-0002-1531-3291"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takahiko Seki","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1531-3291","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5082322594","display_name":"Yasuyuki Kaneta","orcid":"https://orcid.org/0000-0003-2799-2487","observed_orcids":["https://orcid.org/0000-0003-2799-2487"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yasuyuki Kaneta","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2799-2487","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.949999988079071},{"id":"https://openalex.org/keywords/atp-competitive-inhibitors","display_name":"ATP-competitive inhibitors","score":0.9110000133514404},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.7599999904632568},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9649999737739563},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.9110000133514404},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.3919999897480011}],"concepts":[{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.7538999915122986},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7128999829292297},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6625999808311462},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.42489999532699585},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.37770000100135803},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.31150001287460327},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.31060001254081726},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.3050999939441681},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.2881999909877777},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.28110000491142273},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2791000008583069},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.2623000144958496},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.25459998846054077},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2533999979496002}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.30733800","doi":"https://doi.org/10.1158/1535-7163.30733800","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30733800","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30733800","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Methods_from_Discovery_of_a_Novel_ATP-Competitive_MEK_Inhibitor_DS03090629_that_Overcomes_Resistance_Conferred_by_BRAF_Overexpression_in_BRAF-Mutated_Melanoma/30733800","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.30733800","doi":"https://doi.org/10.1158/1535-7163.30733800","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30733800","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9074000120162964,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4313880234","https://openalex.org/W4392690229","https://openalex.org/W7098035583","https://openalex.org/W4392681205","https://openalex.org/W2069912173","https://openalex.org/W4234720637","https://openalex.org/W7100853126","https://openalex.org/W4392690383","https://openalex.org/W2106796758","https://openalex.org/W2938387224"],"abstract_inverted_index":{"Supplementary":[0],"Methods":[1],"from":[2],"Discovery":[3],"of":[4],"a":[5],"Novel":[6],"ATP-Competitive":[7],"MEK":[8],"Inhibitor":[9],"DS03090629":[10],"that":[11],"Overcomes":[12],"Resistance":[13],"Conferred":[14],"by":[15],"BRAF":[16],"Overexpression":[17],"in":[18],"BRAF-Mutated":[19],"Melanoma":[20]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2025-11-28T00:00:00"}